XXXX in older adults: the clinical profile and impact of interferon Beta treatment.

@entity1 @entity17229 @entity66 @entity2391 @entity717 @entity15
Background. We examined (1) @entity1 characteristics and @entity66 ( @entity66 ) exposure in late-onset (LOMS, >= 50 years at symptom onset) versus adult-onset (AOMS, 18-<50 years) @entity15 and (2) the association between interferon-beta ( @entity2391 ) and disability progression in older relapsing-onset @entity15 adults (>= 50 years). Methods. This retrospective study (1980-2004, British Columbia, Canada) included 358 LOMS and 5627 AOMS @entity1 . @entity2391 -treated relapsing-onset @entity15 @entity1 aged >= 50 (regardless of onset age, 90) were compared with 171 contemporary and 106 historical controls. Times to EDSS 6 from onset and from @entity2391 eligibility were examined using survival analyses. Results. LOMS @entity1 (6%) were more likely to be male, with motor onset and a primary-progressive course, and exhibit faster progression and were less likely to take @entity17229 . Nonetheless, 57% were relapsing-onset, of which 31% were prescribed @entity17229 , most commonly @entity2391 . Among older relapsing-onset @entity15 adults, no significant association between @entity2391 exposure and disability progression was found when either the contemporary (hazard ratio [HR]: 0.46; 95% CI: 0.18-1.22) or historical controls (HR: 0.54; 95% CI: 0.20-1.42) were considered. Conclusion. LOMS differed clinically from AOMS. One-third of older relapsing-onset @entity15 @entity1 were prescribed a @entity66 . @entity2391 exposure was not significantly associated with @entity717 in older @entity15 @entity1 .
